KMT2A and leukemia: Epigenetic inhibitors that were initially developed by studying MLL-FP leukemias [14,15,16] have an impact on a much wider range of different cancers [277,279], suggesting MLL-FP leukemias may provide a useful model for studying the role of epigenetics in human disease in general.